Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis licenses Debiopharm's Debio025 for HCV; Debiopharm regains rights

Executive Summary

Novartis has received exclusive development, manufacturing, and marketing rights (excluding Japan) to fellow Swiss pharma developer Debiopharm's Phase IIb Debio025 (alisporivir), a first-in-class cyclophilin inhibitor for hepatitis C.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies